Myelodysplastic syndromes, version 2.2015 featured updates to the NCCN guidelines

Peter L. Greenberg; Richard M. Stone; Rafael Bejar; John M. Bennett; Clara D. Bloomfield; Uma Borate; Carlos M. De Castro; H. Joachim Deeg; Amy E. DeZern; Amir T. Fathi; Olga Frankfurt; Karin Gaensler; Guillermo Garcia-Manero; Elizabeth A. Griffiths; David Head; Virginia Klimek; Rami Komrokji; Lisa A. Kujawski; Lori J. Maness; Margaret R. O'Donnell; Daniel A. Pollyea; Bart Scott; Paul J. Shami; Brady L. Stein; Peter Westervelt; Benton Wheeler; Dorothy A. Shead; Courtney Smith

doi:10.6004/jnccn.2015.0038

Myelodysplastic syndromes, version 2.2015 featured updates to the NCCN guidelines

Peter L. Greenberg, Richard M. Stone, Rafael Bejar, John M. Bennett, Clara D. Bloomfield, Uma Borate, Carlos M. De Castro, H. Joachim Deeg, Amy E. DeZern, Amir T. Fathi, Olga Frankfurt, Karin Gaensler, Guillermo Garcia-Manero, Elizabeth A. Griffiths, David Head, Virginia Klimek, Rami Komrokji, Lisa A. Kujawski, Lori J. Maness, Margaret R. O'DonnellDaniel A. Pollyea, Bart Scott, Paul J. Shami, Brady L. Stein, Peter Westervelt, Benton Wheeler, Dorothy A. Shead, Courtney Smith

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Review article › peer-review

34 Scopus citations

Abstract

The NCCN Guidelines for Myelodysplastic Syndromes (MDS) comprise a heterogeneous group of myeloid disorders with a highly variable disease course that depends largely on risk factors. Risk evaluation is therefore a critical component of decision-making in the treatment of MDS. The development of newer treatments and the refinement of current treatment modalities are designed to improve patient outcomes and reduce side effects. These NCCN Guidelines Insights focus on the recent updates to the guidelines, which include the incorporation of a revised prognostic scoring system, addition of molecular abnormalities associated with MDS, and refinement of treatment options involving a discussion of cost of care.

Original language	English (US)
Pages (from-to)	261-272
Number of pages	12
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	13
Issue number	3
DOIs	https://doi.org/10.6004/jnccn.2015.0038
State	Published - Mar 1 2015

ASJC Scopus subject areas

Oncology

Access to Document

10.6004/jnccn.2015.0038

Fingerprint Dive into the research topics of 'Myelodysplastic syndromes, version 2.2015 featured updates to the NCCN guidelines'. Together they form a unique fingerprint.

Cite this

Greenberg, P. L., Stone, R. M., Bejar, R., Bennett, J. M., Bloomfield, C. D., Borate, U., De Castro, C. M., Deeg, H. J., DeZern, A. E., Fathi, A. T., Frankfurt, O., Gaensler, K., Garcia-Manero, G., Griffiths, E. A., Head, D., Klimek, V., Komrokji, R., Kujawski, L. A., Maness, L. J., ... Smith, C. (2015). Myelodysplastic syndromes, version 2.2015 featured updates to the NCCN guidelines. JNCCN Journal of the National Comprehensive Cancer Network, 13(3), 261-272. https://doi.org/10.6004/jnccn.2015.0038

Greenberg, Peter L. ; Stone, Richard M. ; Bejar, Rafael ; Bennett, John M. ; Bloomfield, Clara D. ; Borate, Uma ; De Castro, Carlos M. ; Deeg, H. Joachim ; DeZern, Amy E. ; Fathi, Amir T. ; Frankfurt, Olga ; Gaensler, Karin ; Garcia-Manero, Guillermo ; Griffiths, Elizabeth A. ; Head, David ; Klimek, Virginia ; Komrokji, Rami ; Kujawski, Lisa A. ; Maness, Lori J. ; O'Donnell, Margaret R. ; Pollyea, Daniel A. ; Scott, Bart ; Shami, Paul J. ; Stein, Brady L. ; Westervelt, Peter ; Wheeler, Benton ; Shead, Dorothy A. ; Smith, Courtney. / Myelodysplastic syndromes, version 2.2015 featured updates to the NCCN guidelines. In: JNCCN Journal of the National Comprehensive Cancer Network. 2015 ; Vol. 13, No. 3. pp. 261-272.

@article{3d3255ec6797476aba76a33bb7923b10,

title = "Myelodysplastic syndromes, version 2.2015 featured updates to the NCCN guidelines",

abstract = "The NCCN Guidelines for Myelodysplastic Syndromes (MDS) comprise a heterogeneous group of myeloid disorders with a highly variable disease course that depends largely on risk factors. Risk evaluation is therefore a critical component of decision-making in the treatment of MDS. The development of newer treatments and the refinement of current treatment modalities are designed to improve patient outcomes and reduce side effects. These NCCN Guidelines Insights focus on the recent updates to the guidelines, which include the incorporation of a revised prognostic scoring system, addition of molecular abnormalities associated with MDS, and refinement of treatment options involving a discussion of cost of care.",

author = "Greenberg, {Peter L.} and Stone, {Richard M.} and Rafael Bejar and Bennett, {John M.} and Bloomfield, {Clara D.} and Uma Borate and {De Castro}, {Carlos M.} and Deeg, {H. Joachim} and DeZern, {Amy E.} and Fathi, {Amir T.} and Olga Frankfurt and Karin Gaensler and Guillermo Garcia-Manero and Griffiths, {Elizabeth A.} and David Head and Virginia Klimek and Rami Komrokji and Kujawski, {Lisa A.} and Maness, {Lori J.} and O'Donnell, {Margaret R.} and Pollyea, {Daniel A.} and Bart Scott and Shami, {Paul J.} and Stein, {Brady L.} and Peter Westervelt and Benton Wheeler and Shead, {Dorothy A.} and Courtney Smith",

year = "2015",

month = mar,

day = "1",

doi = "10.6004/jnccn.2015.0038",

language = "English (US)",

volume = "13",

pages = "261--272",

journal = "Journal of the National Comprehensive Cancer Network : JNCCN",

issn = "1540-1405",

publisher = "Cold Spring Publishing LLC",

number = "3",

}

Greenberg, PL, Stone, RM, Bejar, R, Bennett, JM, Bloomfield, CD, Borate, U, De Castro, CM, Deeg, HJ, DeZern, AE, Fathi, AT, Frankfurt, O, Gaensler, K, Garcia-Manero, G, Griffiths, EA, Head, D, Klimek, V, Komrokji, R, Kujawski, LA, Maness, LJ, O'Donnell, MR, Pollyea, DA, Scott, B, Shami, PJ, Stein, BL, Westervelt, P, Wheeler, B, Shead, DA & Smith, C 2015, 'Myelodysplastic syndromes, version 2.2015 featured updates to the NCCN guidelines', JNCCN Journal of the National Comprehensive Cancer Network, vol. 13, no. 3, pp. 261-272. https://doi.org/10.6004/jnccn.2015.0038

Myelodysplastic syndromes, version 2.2015 featured updates to the NCCN guidelines. / Greenberg, Peter L.; Stone, Richard M.; Bejar, Rafael; Bennett, John M.; Bloomfield, Clara D.; Borate, Uma; De Castro, Carlos M.; Deeg, H. Joachim; DeZern, Amy E.; Fathi, Amir T.; Frankfurt, Olga; Gaensler, Karin; Garcia-Manero, Guillermo; Griffiths, Elizabeth A.; Head, David; Klimek, Virginia; Komrokji, Rami; Kujawski, Lisa A.; Maness, Lori J.; O'Donnell, Margaret R.; Pollyea, Daniel A.; Scott, Bart; Shami, Paul J.; Stein, Brady L.; Westervelt, Peter; Wheeler, Benton; Shead, Dorothy A.; Smith, Courtney.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 13, No. 3, 01.03.2015, p. 261-272.

Research output: Contribution to journal › Review article › peer-review

TY - JOUR

T1 - Myelodysplastic syndromes, version 2.2015 featured updates to the NCCN guidelines

AU - Greenberg, Peter L.

AU - Stone, Richard M.

AU - Bejar, Rafael

AU - Bennett, John M.

AU - Bloomfield, Clara D.

AU - Borate, Uma

AU - De Castro, Carlos M.

AU - Deeg, H. Joachim

AU - DeZern, Amy E.

AU - Fathi, Amir T.

AU - Frankfurt, Olga

AU - Gaensler, Karin

AU - Garcia-Manero, Guillermo

AU - Griffiths, Elizabeth A.

AU - Head, David

AU - Klimek, Virginia

AU - Komrokji, Rami

AU - Kujawski, Lisa A.

AU - Maness, Lori J.

AU - O'Donnell, Margaret R.

AU - Pollyea, Daniel A.

AU - Scott, Bart

AU - Shami, Paul J.

AU - Stein, Brady L.

AU - Westervelt, Peter

AU - Wheeler, Benton

AU - Shead, Dorothy A.

AU - Smith, Courtney

PY - 2015/3/1

Y1 - 2015/3/1

N2 - The NCCN Guidelines for Myelodysplastic Syndromes (MDS) comprise a heterogeneous group of myeloid disorders with a highly variable disease course that depends largely on risk factors. Risk evaluation is therefore a critical component of decision-making in the treatment of MDS. The development of newer treatments and the refinement of current treatment modalities are designed to improve patient outcomes and reduce side effects. These NCCN Guidelines Insights focus on the recent updates to the guidelines, which include the incorporation of a revised prognostic scoring system, addition of molecular abnormalities associated with MDS, and refinement of treatment options involving a discussion of cost of care.

AB - The NCCN Guidelines for Myelodysplastic Syndromes (MDS) comprise a heterogeneous group of myeloid disorders with a highly variable disease course that depends largely on risk factors. Risk evaluation is therefore a critical component of decision-making in the treatment of MDS. The development of newer treatments and the refinement of current treatment modalities are designed to improve patient outcomes and reduce side effects. These NCCN Guidelines Insights focus on the recent updates to the guidelines, which include the incorporation of a revised prognostic scoring system, addition of molecular abnormalities associated with MDS, and refinement of treatment options involving a discussion of cost of care.

UR - http://www.scopus.com/inward/record.url?scp=84924366934&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924366934&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2015.0038

DO - 10.6004/jnccn.2015.0038

M3 - Review article

C2 - 25736003

AN - SCOPUS:84924366934

VL - 13

SP - 261

EP - 272

JO - Journal of the National Comprehensive Cancer Network : JNCCN

JF - Journal of the National Comprehensive Cancer Network : JNCCN

SN - 1540-1405

IS - 3

ER -